The main objective of this study is to evaluate the effect of vitamin D3 on diabetic
individual with painful neuropathy in a tertiary healthcare.
The people with diabetes (type 1 and type 2) who have a Douleur Neuropathique 4 (DN4) score
≥4 will be considered eligible in this prospective study. Their serum samples will be
subjected to pre-and post-biochemical screening of serum 25 (OH) D and HbA1c. The individual
having Vitamin D insufficiency and deficiency will be administered a single dose of oral
Vitamin D3 (Soft Gel capsule 200,000 IU), and follow-up for post-biochemical screening after
3 months.